Tomorrow, 5 December 2025, is the last day of trading in Prostatype Genomic AB’s ("Prostatype" or the "Company") warrants of series TO 4, which were issued in connection with the Company’s rights issue of units in August 2024. The final day to utilize warrants for subscription of new shares is 9 December 2024.

In August 2024, the Company carried out a preferential rights issue which, including a directed issue to guarantors resulted in the issuance of 1,663,016,092 warrants of series TO 4. Terms for exercising warrants, after adjustment due to the reverse share split on October 31, 2024, are that a thousand (1,000) warrants of series TO 4 grant the right to subscribe for one (1) new share in Prostatype during the exercise period, which runs from 25 November to 9 December 2024. The subscription price for TO 4 has been set at 5.96 SEK per share. If all warrants of series TO 4 are fully exercised, the Company will receive approximately 9.9 million SEK before issuance costs.

In order for warrants not to expire without value, the holder is required to subscribe for new shares, by exercising warrants, no later than 9 December 2024, or sell warrants no later than tomorrow 5 December 2024.

To note, if the warrants are owned through an investments savings account (Sw. ISK) or an endowment insurance (Sw. Kapitalförsäkring), warrant holders should contact their nominee well in advance for further instructions regarding the exercise of Warrants, as different nominees have different processing times.

Complete terms and instructions for warrants of series TO 4 are available on the Company's website (www.prostatypegenomics.com). An information folder containing summary information about the warrant exercise is available on Prostatype's and Nordic Issuing AB's (www.nordic-issuing.se) respective websites during the exercise period.

Advisors
In connection with the warrant exercise, Prostatype has engaged Gemstone Capital A/S as financial advisor, Advokatfirman Lindahl KB as legal advisor and Nordic Issuing AB as issuing agent.

For more information, please contact:
Fredrik Rickman, VD
Tel: +46 (0)73-049 77 01
E-mail: fredrik.rickman@prostatypegenomics.com

About Prostatype
Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision support tool to answer the question of radical treatment or no radical treatment of prostate cancer. The test was developed by a leading research group at Karolinska Institutet and is provided by Prostatype Genomics AB.

Important Information
This press release does not constitute an offer to acquire, subscribe for, or otherwise trade in shares, warrants, unit rights, BTUs, or other securities in Prostatype Genomics AB. Investors should not subscribe for or acquire any securities other than on the basis of the information in the prospectus published prior to the commencement of the subscription period in the Rights Issue. No action has been or will be taken to allow a public offering in any jurisdictions other than Sweden.

This press release may not be released, published, or distributed, directly or indirectly, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, the United Kingdom, South Africa, South Korea, Russia, Belarus, or any other jurisdiction where the distribution of this press release would be unlawful. This press release does not constitute an offer to sell new shares, warrants, subscription rights, BTUs, or other securities to any person in a jurisdiction where such an offer would be unlawful or would require prospectuses, additional registration, or other measures beyond those required by Swedish law. The prospectus and other documents related to the Rights Issue may not be distributed in or into any country where such distribution or the Rights Issue requires actions as mentioned above or where it would conflict with the regulations of such country. Any actions in violation of these instructions may constitute a breach of applicable securities laws.

No shares, warrants, unit rights, BTUs, or other securities have been or will be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or under the securities laws of any state or other jurisdiction of the United States, and may not be offered, subscribed for, exercised, pledged, sold, resold, allotted, delivered, or otherwise transferred, directly or indirectly, in or into the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities laws of the relevant state or other jurisdiction of the United States.

This press release may contain certain forward-looking statements reflecting the Company's current views on future events as well as financial and operational developments. Words such as "intends," "assesses," "expects," "may," "plans," "believes," "estimates," and other expressions indicating or predicting future developments or trends and that are not based on historical facts constitute forward-looking statements. Forward-looking statements are, by nature, associated with both known and unknown risks and uncertainties, as they depend on future events and circumstances. Forward-looking statements do not constitute a guarantee of future results or developments, and actual outcomes may differ materially from what is expressed in the forward-looking statements. Neither the Company nor any other party undertakes to review, update, confirm, or publicly announce any revisions of any forward-looking statements to reflect events that occur or circumstances that arise with regard to the content of this press release, unless required by law or the Nasdaq First North Growth Market's regulations.